Siemens Healthineers Presents Two Revolutionary High-End MRI Scanners for Clinical and Scientific Use

Siemens Healthineers
  • 7 Tesla (T) Magnetom Terra.X(1) will offer excellent imaging of even the smallest structures
  • 3T Magnetom Cima.X(2) more than doubles the gradient amplitude(3)
  • AI algorithms which can reduce scanning times by up to 50%(4) now available in this high-end segment

Siemens Healthineers presents its two latest magnetic resonance tomographs designed for clinical and scientific use at the Siemens Healthineers Shape 23 Keynote: Magnetom Cima.X with 3T field strength and Magnetom Terra.X with 7T. "Due to their high field strengths and strong gradient performance, both scanners will be optimal for detecting the finest structures in the body more clearly. By introducing AI-based algorithms on these high-end scanners for the first time, we reduce the scanning time in MRI by up to 50%, while improving image quality," says Arthur Kaindl, Head of Magnetic Resonance Imaging at Siemens Healthineers.

Magnetom Cima.X

The 3T Magnetom Cima.X will use the company's strongest gradient with an amplitude(5) of 200 mT/m and a slew rate of 200 T/m/s. This is 2.5 times higher than the currently strongest MRI from Siemens Healthineers. Such a high gradient can help to better understand neurodegenerative diseases such as multiple sclerosis, even between relapses(6). So-called microstructures can be visible more clearly with the help of the strong gradients(6) and could play a major role in understanding these diseases. Microstructures can hardly be visualized with classical MR imaging. Thus, treatment could be initiated earlier, improving the outlook for patients.

Magnetom Terra.X

Magnetom Terra.X with a field strength of 7T represents the cutting edge of commercial MR imaging. The system will be the successor to Magnetom Terra, the first 7T clinical system, launched in 2017. The higher signal at 7T enables very high-resolution imaging for example of the head. This is particularly important in diseases where the detection of the smallest lesions can be crucial for the further treatment. Even in the field of knee imaging, the visibility of the smallest lesions can mean the decision for or against a surgery. The new hardware and software from Magnetom Terra.X, named "Ultra IQ technology" by Siemens Healthineers, significantly will increase the capabilities of a 7T system: MR imaging at these extremely high field strengths can lead to a darkening of the image impression for instance at the lower part of the head. With Magnetom Terra.X, potentially relevant findings are clearly visible even along the edges of the image. While classic MR imaging works especially well in body regions with a lot of water in the tissue, other substances in the body, such as sodium, can be better visualized with high field strengths. This form of imaging goes beyond the mere representation of anatomy and enables a visualization of processes in the body such as the metabolism.

Especially for research applications, both new scanners will offer extensive innovations, such as the new Open Recon platform(7): "Open Recon allows us to run the reconstruction algorithms we have developed directly on the scanner. For the first time, we can transfer our research developments more easily, efficiently, and effectively into clinical routine," says Prof. Matthias Stuber from the University of Lausanne. In addition, both scanners will offer assistance systems that support scan preparation and the scan itself. Even these complex systems will be easy to operate for every user. The training effort will be minimal, and the scanners can be seamlessly integrated into the fleet.

Further information on Magnetom Cima.X can be found at www.siemens-healthineers.com/magnetic-resonance-imaging/3t-mri-scanner/magnetomcima-x.

For more information on Magnetom Terra.X, please visit www.siemens-healthineers.com/magnetic-resonance-imaging/7t-mri-scanner/magnetomterra-x.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

1. Magnetom Terra.X is under development and is not commercially available. Future availability cannot be guaranteed.
2. Magnetom Cima.X is under development and is not commercially available. Future availability cannot be guaranteed.
3. Compared to other systems from Siemens Healthineers.
4. Based on data acquired on Magnetom Cima.X. Data on file.
5. >= 200 (+-3% for design tolerances)
6. Huang, S. Y., Nummenmaa, A., Witzel, T., Duval, T., Cohen-Adad, J., Wald, L. L., & McNab, J. A. (2015). The impact of gradient strength on in vivo diffusion MRI estimates of axon diameter. NeuroImage, 106, 464–472. https://doi.org/10.1016/j.neuroimage.2014.12.008
7. Open Recon is to add clinical reconstructions to the system, if signed and released for clinical use by SHS. Any other recon used e.g., by researchers is automatically labelled not for diagnostic use, which may require observation of national regulations.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...